Department of Neurology, the Jikei University School of Medicine, Japan.
Department of Neurology, the Jikei University Katsushika Medical Center, Japan.
Intern Med. 2023 Jan 1;62(1):33-42. doi: 10.2169/internalmedicine.8940-21. Epub 2022 Feb 1.
Parkinson's disease (PD) is a neurodegenerative disease manifesting with motor and non-motor symptoms. Current treatment mainly relies on medication as a symptomatic therapy modulating neurotransmitters. Dopamine replacement therapy has been established, and levodopa is the gold standard for treatment of PD. However, the emergence of motor complications, such as a wearing-off phenomenon, is a clinical problem. Both primary symptoms and motor complications have been targets for the development of treatments for PD. Recent progression in the management of motor complications is supported by newly developed agents and advances in device and formulation technology to deliver drugs continuously. Elucidation of the pathophysiology of PD and the development of disease-modifying therapy that affects the underlying fundamental pathophysiology of the disease are also progressing. In this review, we introduce current knowledge on developments concerning medications for patients with PD.
帕金森病（PD）是一种神经退行性疾病，表现为运动和非运动症状。目前的治疗主要依赖于药物，作为调节神经递质的对症治疗。多巴胺替代疗法已经确立，左旋多巴是治疗 PD 的金标准。然而，运动并发症的出现，如“开-关”现象，是一个临床问题。原发性症状和运动并发症一直是 PD 治疗发展的目标。最近在管理运动并发症方面的进展得到了新开发的药物和药物输送装置和配方技术的进步的支持。PD 的病理生理学的阐明和影响疾病潜在根本病理生理学的疾病修饰治疗的发展也在进展。在这篇综述中，我们介绍了目前关于 PD 患者药物治疗发展的知识。
